On September 18, 2026, Nasus Pharma Ltd. entered into an At-The-Market Sales Agreement with BTIG, LLC to offer and sell ordinary shares from time to time as agent under its effective Form F-3 registration statement. The company is not obligated to sell any specific amount of shares but intends to use net proceeds for the ongoing clinical development of NS002 for anaphylaxis treatment, initiating studies for other pipeline products, and working capital. The sales agent receives a commission of up to 3.0% of aggregate gross proceeds. Nasus Pharma Ltd. operates in the biopharmaceutical industry, focusing on drug discovery and development.
